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Evaluation of a home-based standing frame programme in people with 
progressive Multiple Sclerosis (SUMS): a pragmatic, multi-centre, randomised, 
controlled trial and cost-effectiveness analysis. 
  
ABSTRACT / SUMMARY 
Background: 
People severely impaired with progressive Multiple Sclerosis (MS) spend much of 
their day sitting, with very few options to improve motor function. In response, 
secondary physical and psychosocial complications can occur. Effective and feasible 
self-management strategies are needed to reduce sedentary behaviour and enhance 
motor function. We aimed to assess the clinical and cost-effectiveness of a home-
based, self-managed, standing frame programme.  
 
Methods:   
A pragmatic, multi-centre (n=8, two regions in the United Kingdom), randomised 
controlled superiority trial of people with progressive MS and severe mobility 
impairment, with assessor-blinded outcome assessment using clinician and patient 
rated measures at baseline, 20 and 36 weeks. Following baseline assessment, 
participants were randomised (1:1) by computer-generated assignment to either a 
standing programme plus usual care or usual care alone. The intervention consisted 
of two home-based physiotherapy sessions (60 minutes each) to set up the standing 
programme, supported by 6 follow-up telephone calls (15-minutes/call). Participants 
were asked to stand for 30 minutes, 3 times weekly, over 20 weeks, with 
encouragement to continue in the longer term, although no further physiotherapy 
support was provided.  
 
The primary clinical outcome was motor function (Amended Motor Club Assessment, 
AMCA) at week 36, analysed in the intention-to-treat (ITT) population. A 9-point 
AMCA change was considered clinically meaningful a priori. Adverse events were 
collected by a daily pre-formatted patient diary throughout the 36 weeks. An 
economic evaluation established the resources required to provide the standing 
programme, estimated intervention costs, and conducted a cost-effectiveness 
analysis.  
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The trial registration is ISRCTN69614598. 
 
Findings:  
Between 16th September 2015 and 28th April 2017, 285 people with progressive MS 
were screened for eligibility and 140 were randomly assigned; 71 (intervention) and 
69 (control). Of these, 122 completed the primary outcome (intervention = 61, control 
= 61) for the ITT analysis. Most people in the intervention group (66%) stood 
regularly over the 36 week trial period. Standing resulted in a significant increase in 
AMCA compared to usual care alone, with fully adjusted between-group difference in 
AMCA at 36 weeks of 4.7 points (95% confidence interval: 1.9 to 7.5). For the patient 
diarised adverse events (AEs), there was a disparity between the two groups in the 
frequency of short-term musculoskeletal pain (standing group = 486 of all 1188 AEs 
(41%); usual care group = 160 of all 736 AEs (21%)) which was potentially related to 
the intervention. The musculoskeletal pain lasted for over seven days in five people 
(standing group = 2; usual care group = 3. No serious AEs related to the study 
occurred. The additional quality-adjusted life-years (QALYs) in the standing 
programme group were 0.018, and the estimated incremental cost-per-QALY was 
approximately £14,700.  
 
Interpretation:  
The standing programme significantly increased motor function in people with severe 
progressive MS, although not to the degree that was considered a priori as clinically 
meaningful. This is one of the first physiotherapy interventions proven to be effective 
in this group of people. We have demonstrated that the programme is feasible as a 
home-based, self-managed intervention which could be routinely implemented in 
clinical practice in the United Kingdom. 
 
Funding:  
UK National Institute of Health Research (Research for Patient Benefit Programme) 
(PB-PG-1013-32047), United Kingdom.  
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RESEARCH IN CONTEXT  
Evidence before this study  
The long-term management of people with progressive Multiple Sclerosis (MS) is 
challenging, particularly when mobility and balance impairments become severe. To 
investigate the evidence-base for the use of standing frames in people with 
progressive MS, we searched electronic databases (MEDLINE, AMED, CINAHL, 
EMBASE, PsycINFO and PEDro) for manuscripts published in English, in adults >18 
years, from database inception until 1st August, 2018. Search terms were “multiple 
sclerosis” and “standing frames” or “standing tables” or “standing wheelchairs”. 
Reference lists from identified papers were checked and www.clinicaltrials.org and 
the ISRCTN registry searched. No adequately powered randomised controlled trials 
(RCTs) evaluating the clinical or cost-effectiveness of this intervention were 
identified. Our search revealed one systematic review of standing in people with 
upper motor neurone disorders which cited one small pilot RCT in MS (n=6), and one 
mixed methods study (AB case study design plus interviews, n=9), neither of which 
exclusively recruited people with progressive MS. To our knowledge, no RCTs of 
standing frame use in people with MS have been undertaken since our literature 
search.  
 
Added value of this study  
To our knowledge, the SUMS study is the largest RCT of physical rehabilitation in 
people with progressive MS. It is the first assessor-blinded, multi-centre, RCT to 
investigate the clinical and cost-effectiveness, safety, and tolerability of a supported 
standing frame programme plus usual care (intervention) versus usual care alone 
(control) in people with progressive MS whose standing balance and walking is 
severely limited. The study is an important addition to the evidence-base for 
supported standing, for which high-level evidence is currently lacking.  
 
Implications of all the available evidence  
The use of a home-based, self-managed standing frame programme can provide a 
significant improvement in motor function at an estimated incremental cost of 
approximately £14,700 per quality-adjusted life-year (QALY) and a 0.52 to 0.61 
probability of being cost-effective at the National Institute of Health and Care 
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Excellence threshold of £20,000 to £30,000 per QALY. The intervention was well 
tolerated in people with MS who were unable to walk or whose mobility is limited to a 
maximum of 20 metres with a bilateral walking aid. The standing programme 
significantly increased motor function in people with progressive MS although not to 
the degree that was considered a priori as clinically meaningful. Participants varied 
in their response to standing, but on average, longer standing times were associated 
with significantly greater improvements in motor function, with the confidence 
intervals containing the a priori clinically meaningful improvement. 
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MAIN BODY OF TEXT  
Introduction  
Multiple Sclerosis (MS) is a progressive, neurological condition, impacting all aspects 
of people’s lives. Affecting approximately 2.5 million people worldwide, it 
substantially and adversely impacts on an individual’s quality of life. MS is 
associated with high direct and indirect costs to people with MS, their families and 
society. These costs are highly correlated with increasing immobility.1  
 
Mobility is a major concern for people with MS.2 It is estimated that within 10-15 
years of diagnosis, approximately 80% of people will experience impaired mobility. 
Eventually, an estimated 25% are wheelchair dependent.3 Mobility spans more than 
walking, and includes standing, transferring and moving in bed.4 These are important 
activities for maintaining independence, particularly for people who are severely 
physically impaired. Individuals with progressive MS spend much of their day sitting5, 
often with limited ability to change position. In response, insidious yet preventable 
secondary complications can occur including muscle wasting, reduced skin integrity, 
spasms, constipation, depression and lowered self-esteem.6 These problems can 
compound the primary neurological disability, accelerating loss of independence, 
and can even be mistaken for disease progression. Furthermore, prolonged sitting 
time is associated with increased risks of morbidity and mortality.5 The clinical 
significance of these issues is underlined by their consistent prominence in policy 
documents for long-term neurological conditions.4,7 
 
There is strong evidence that increasing physical activity can improve mobility and 
minimise secondary health problems in people with mild to moderate MS8, and 
evidence suggests that this may also be the case for people with severe MS.9,10 
Despite this, up to 78% of people with MS do not participate in meaningful physical 
activity.11 There are considerably more barriers to keeping active when mobility 
impairment is severe12. Interventions have typically been resource intensive, 
entailing regular supervised sessions by a physiotherapist or sports therapist, within 
an outpatient or hospital setting, and relying on expensive equipment which cannot 
be used within the home environment.9,10 Moreover, data are currently lacking 
regarding adherence when supervision ceases.  
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Finite healthcare resources mean on-going supervision of physical activity 
programmes is rarely possible. Effective self-management strategies, which are low 
cost and realistic to implement, are needed for people with severe physical 
limitations to optimise their engagement in physical activity. Regular supported 
standing using standing frames, which can be used within people’s homes, is one 
such option. Standing frames enable individuals with restricted mobility and balance, 
lower limb or trunk control, the opportunity to spend time in supported standing. 
Proposed benefits of standing include strengthening antigravity muscles, providing 
prolonged weight-bearing muscle stretch, enhancing respiratory function, and 
maintaining bone density6. Whilst preliminary evidence demonstrates benefit for their 
use in in people with MS13-15, no appropriately powered RCTs have been 
undertaken. In line with Newman et al’s systematic review6 findings, we concluded it 
was important to determine whether a home-based standing frame programme was 
clinically effective and to explore its cost-effectiveness in people with severe, 
progressive MS.    
 
Methods 
The trial methodology, previously published in detail16, is briefly described in line with 
current guidelines17-20.  
 
The trial is registered with the International Standard Randomised Controlled Trials 
Number:  ISRCTN69614598. 
 
Study Design and Participants  
This was an individually-randomised, controlled, pragmatic, multi-centre, superiority 
trial with blinded outcome assessments in people with progressive MS. Participants 
were randomised to receive either usual care or usual care plus standing 
programme, with blinded assessments at baseline and 20 weeks post-randomisation 
(aligned with end of the protocolised intervention period for those allocated to the 
intervention group) and again 16 weeks later (36 weeks post-randomisation).   
 
Participants were recruited through eight healthcare organisations, including National 
Health Service (NHS) Trusts, Social Enterprises and third sector MS Therapy 
Centres, in two regions (Devon/Cornwall and East Anglia) of the United Kingdom 
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(UK). Individuals were invited consecutively until the allocated number of frames 
(dependent on commissioning costs) at each healthcare organisation had been 
reached. Key inclusion criteria were: individuals aged over 18 years with a diagnosis 
of progressive MS (primary or secondary) according to McDonald’s criteria21, and 
scoring 6.5–8.0 on the Expanded Disability Status Scale (EDSS). Key exclusion 
criteria were: within three months of ceasing an MS disease modifying drug, 
receiving steroid treatment within the last month or participating in another clinical 
trial. Full inclusion/exclusion criteria are reported in the protocol paper.16   
 
In this ethically approved study (NRES Committee South West – Frenchay, REC 
reference number: 15/SW/0088) participants were provided with written informed 
consent before enrolment or undertaking any study-related procedures.  
 
Randomisation and Masking 
The 1:1 allocation sequence was undertaken using random-sized permuted blocks, 
stratified by region (Devon/Cornwall or East Anglia) and baseline EDSS score (≤7.0 
or ≥7.5). It was computer-generated in conjunction with an independent statistician 
who had no further involvement in the trial. The randomisation list and programme 
that generated it were stored in a secure network location within the UKCRC-
registered Peninsula Clinical Trials Unit (PenCTU), accessible only to those 
responsible for providing the system. Randomisation took place following baseline 
assessment, with the blinded assessor inputting the participant details directly into 
the randomisation website.  
 
It was not possible to blind trial participants, carers or treating physiotherapists due 
to the nature of the intervention. However, outcome assessors (research therapists) 
were blinded to treatment allocation and all assessments were conducted 
independently and away from the participant’s home. At each assessment time-
point, research therapists were asked whether they were unblinded to group 
allocation, with 89% and 87% answering no at weeks 20 and 36, respectively. The 
trial statisticians were blinded for the primary analysis of the primary outcome. 
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Interventions  
Participants allocated to the standing group were issued with a wooden Oswestry Standing 
frame (Theo Davies & Sons, Wrexham, North Wales, http://www.oswestry-frames.co.uk/), 
funded via the UK NHS commissioning process and delivered to the person’s home prior to 
the first physiotherapy session. The person with MS and their standing assistant (typically 
their spouse) engaged in two face-to-face, home-based, one-hour physiotherapy sessions, 
aimed at setting up, implementing and progressing the standing programme according to 
ability, supplemented by on-line advice and DVDs. These were supported by six scripted 
telephone calls which utilised a behaviour change approach22 to increase the participant’s 
self-efficacy, intended to enhance long-term engagement.  
 
In line with previous research14 participants were asked to stand in the frame for 30 
minutes, three times per week over 20 weeks and to record the frequency and duration of 
each stand in a daily diary. This allowed for a graduated introduction to standing. At the 
end of the 20 week period participants were encouraged to continue to regularly stand 
although no further physiotherapy support was provided. On trial completion, participants 
were able to keep the frame, providing they used it at least once per week.  
 
Use of standing frames is a recognised core skill for UK trained neurological 
physiotherapists. To standardise and optimise implementation of the intervention, 
educational materials were provided and assessment of fidelity undertaken16.  
 
All participants received their usual health and social service input throughout the 
study period.16 This input was recorded on a self-report health and social care 
resource form, which included changes in medication.  
 
Outcomes 
Validated outcome measures included clinician-rated assessments and self-reported 
questionnaires. The primary outcome was motor function as measured by the 
Amended Motor Club Assessment (AMCA)23 at the primary end-point of 36 weeks 
post-randomisation. This was developed for use by physiotherapists in a clinical 
setting to assess motor function in people with MS and has demonstrated validity, 
reliability and responsiveness.14,23,24 The AMCA score (range 0-76) is the sum of two 
sub-scores. The functional activity sub-score (16 items, each scored 0 - 3) comprises 
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key functional activities of the trunk and lower limbs, such as rolling in bed, sit-to-
stand, sitting and standing balance. The lower limb movement sub-score (14 items, 
each scored 0 - 2) rates motor impairment by grading hip and knee flexion, knee 
flexion and dorsiflexion in lying, sitting and standing positions.  
 
Secondary outcomes, at weeks 20 and 36, measured explanatory physical 
impairments16 (length of hip flexors, hamstrings and ankle plantarflexors [manual 
goniometry], knee extensor strength [hand-held dynamometer], spasm frequency 
[Penn Spasm Frequency Scale] and forced expiratory volume at one second [hand-
held spirometer]); clinical outcomes (bowel and bladder control [bladder and bowel 
control scales], sitting balance [modified functional reach in sitting] and falls 
frequency); and quality of life (29-item Multiple Sclerosis Impact Scale (MSIS-29 
version 2)). AMCA at week 20 and the two AMCA sub-scores at 36 weeks were also 
measured as secondary outcomes. Participants were classified as “fallers” if they 
self-reported falling on two or more days during three different periods: (i) up to week 
20; (ii) up to week 36; and (iii) between weeks 21 and 36. 
  
All participants were asked to record new symptoms, falls and medication changes in 
a daily pre-formatted diary. Intervention participants were asked to record frequency 
and duration of standing sessions and any adverse events experienced.   
 
An embedded qualitative component explored the contemporaneous subjective 
experiences of using a standing frame within daily life, through audio-recorded 
diaries by a sub-group of intervention participants. These data will be reported in a 
future publication. 
 
Statistical Analysis 
The target sample size was based on comparing AMCA scores at week 36 between 
allocated groups, adjusting for baseline AMCA score, and detecting a minimally 
clinically important difference (MCID) of nine points, assuming estimated standard 
deviation of AMCA of 20 and estimated correlation between baseline and week 36 
AMCA of 0.55.16 Detection of a nine point between-group difference with 80% power, 
and at the 5% significance level, required follow-up data from 55 participants per 
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group. We allowed for 20% loss to follow-up/non-completion of primary outcome and 
set the recruitment target at 140 participants.  
 
The analyses were pre-specified in a statistical analysis plan (SAP) approved by the 
Trial Steering Committee before analysis commenced (available at 
https://www.plymouth.ac.uk/research/sums), except the method of analysis of spasm 
frequency, as detailed below. Primary analyses were adjusted for the stratification 
factors (region and baseline EDSS) as fixed effects and baseline scores where 
appropriate (i.e. fully adjusted models); results adjusted for baseline scores only are 
also presented. Estimated between-group differences are presented with two-sided 
95% confidence intervals (CIs), with the two-sided significance level for hypothesis 
testing set at 5%. The analyses were conducted using Stata SE version 14.2. 
 
The primary analysis population was defined as all participants who completed 
baseline and 36-week assessments. The primary analysis of the primary outcome, 
AMCA score at 36 weeks, followed an ITT approach, regardless of compliance to the 
intervention, and utilised an analysis of covariance (ANCOVA) approach. As pre-
specified in the SAP, Complier Average Causal Effect (CACE) sensitivity analyses 
were conducted on the 36 week AMCA scores. This method provides an unbiased 
estimate of the intervention effect, based on those who complied with the standing 
intervention protocol.25 The agreed SAP listed six scenarios that could trigger a 
CACE analysis25 (appendix, pp 2), if at least 20% of participants allocated to the 
intervention group were classed as non-compliers in the scenario. The CACE 
analysis, triggered for all six scenarios, used two-stage least squares instrumental 
variable regression, with treatment allocation as the instrument for the binary 
compliance variable and adjustment for baseline AMCA, region and EDSS 
category.25  
 
A repeated measures model was fitted to the post-baseline AMCA scores, including 
adjustment for baseline AMCA, stratification variables and the interaction term 
between allocated group and time point. Between-group pairwise comparisons at 20 
and 36 weeks were calculated using marginal linear predictions and CIs from the 
fitted model. 
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All secondary outcomes were analysed on an ITT basis, utilising an ANCOVA 
approach, for both fully adjusted models and models with adjustment for baseline 
measures only, except spasm frequency and falls. Ordinal logistic regression was 
pre-specified for the analysis of the 5-level Penn Spasm Frequency Scale, however, 
due to insufficient numbers in some of the response categories, a dichotomisation of 
no spasms/mild spasms versus infrequent spasms/>1 per hour/>10 per hour was 
agreed. Logistic regression was used to analyse the dichotomised Penn Spasm 
Frequency Scale and the binary outcome of fallers/non-fallers with adjustment for 
stratification factors.  
 
Cost-effectiveness Analysis 
A within-trial cost-effectiveness analysis was conducted. This estimated the 
additional costs of delivering the intervention, costs associated with health, social 
care, carer and patient resource use, and quality-adjusted life-years (QALYs) over 
the 36 week trial period. The primary perspective was the UK NHS and Personal 
Social Services (PSS), with a broader societal perspective considered in sensitivity 
analyses. Detailed methods are provided in appendix, pp 3-9. 
 
Patient Involvement 
People with MS were actively involved throughout, including development of the 
research questions, study design, trial management and steering groups, writing 
study materials and dissemination activities. 
 
Role of the Funding Source 
This was an investigator-initiated study. The sponsor and funders had no role in 
study design, data collection, data analysis, data interpretation, or report writing. All 
authors had full access to all study data and responsibility for writing the manuscript. 
The corresponding author had the final responsibility to submit for publication. 
 
Results 
Figure 1 outlines the flow of participants in the trial. Recruitment took place from 16th 
September 2015 to 28th April 2017. Participants were aged on average 59.1 years and 
64.3% (90/140) were female (table 1). Baseline characteristics were broadly consistent 
across the allocated groups. Some imbalances in sex and type of MS were observed: 
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43.7% (31/71) males in the standing group versus 27.5% (19/69) in the usual care 
group and 39.4% (28/71) primary progressive MS in the standing group versus 23.2% 
(16/69) in the usual care group. There was an imbalance in baseline AMCA motor 
function score, with mean (SD) of 26.1 (13.9) points in the standing group and 30.2 
(14.6) points in the usual care group (table 2). 
 
Clinical effectiveness 
At the primary end-point, 36 weeks post-randomisation, the pooled standard 
deviation of AMCA at week 36 was 16.9 points, with a correlation between baseline 
and week 36 AMCA of 0.86. Individual-level changes in AMCA between baseline 
and week 36 assessments by allocated group are shown in appendix, pp 10. The 
AMCA at week 36 was significantly higher in the standing group than the usual care 
group, with fully adjusted between-group mean difference of 4.7 points (95% CI: 1.9 
to 7.5, p=0.001) (table 2). Results of the analysis adjusted for baseline AMCA only 
were similar.   
 
Analyses of both 36-week AMCA sub-scores and short-term AMCA at 20 weeks 
showed significant fully adjusted between-group mean differences in favour of the 
standing group. Short-term, statistically significant differences in favour of the 
standing group were observed at 20 weeks in hip goniometry, knee extensor 
strength and both the physical and psychological components of the MSIS-29 scale 
(appendix, pp 11-13). Longer term, at 36 weeks, significant differences were 
observed in hip and ankle goniometry in favour of the standing group; the short-term 
differences in MSIS-29 were not sustained at 36 weeks (appendix, pp 14-16). The 
proportion of participants having ≥2 falls over weeks 21-36 was significantly lower in 
the standing group, with odds ratio of 0.43 (95% CI: 0.20 to 0.94, p=0.035), but there 
was no significant between-group difference over weeks 1-20 or the full 36 week 
study period. Falling days per person year (PPY) was 9.9 amongst the overall 
sample over the 36 weeks.  
 
Eighteen Serious Adverse Events (SAEs) were reported in 15 participants (usual 
care group = 7, standing group = 8; three participants each experienced two SAEs), 
none of which occurred during or in relation to the standing intervention. These were 
in line with expectation: urinary tract infections (n=8), cardiovascular events (stroke, 
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n=2; arrhythmia, n=1), breast cancer (n=1), falls (n=3, of whom two fractured a hip), 
respiratory infections (n=2), and burns (n=1). In two individuals, pressure sores on 
the heels developed following hospital admission. For one participant, this resulted in 
the inability to continue frame use following hospital discharge despite regular use 
pre-hospitalisation  
 
“New symptoms”, recorded via pre-formatted daily diaries, forms the basis of our AE 
reporting, distinct from the SAE data. Overall, 1924 symptoms were recorded 
(standing group = 1188, usual care group = 736) (table 3). These were expected in 
people with MS3. There was disparity between the groups in the frequency of short-
term musculoskeletal pains such as aching leg muscles (standing group = 486 of all 
1188 AEs [41%]; usual care group = 160 of all 736 AEs [21%]), which was potentially 
related to the intervention. The musculoskeletal pain lasted for over seven days in 
five individuals (standing group = 2; usual care group = 3).  
 
Pre-specified sensitivity analyses of the primary outcome with additional adjustment 
for variables with observed baseline imbalance (sex; type of MS) showed no 
difference in conclusion from the primary analysis results. The planned CACE 
sensitivity analyses realised results consistent with the primary analysis, although 
under the CACE approach the average between-group mean differences were larger 
and all of the CIs included 9.0 (figure 2). The repeated measures modelling gave 
similar results to the primary analysis, with a significant between-group difference in 
mean AMCA score at week 20 of 3.7 points (95% CI: 1.2 to 6.2, p=0.004) and at 
week 36 of 4.5 points (95% CI: 2.0 to 7.0, p<0.001).  
 
Cost effectiveness  
The estimated mean (SD) intervention cost per participant was £808 (£91) 
(appendix. pp 17). The main cost drivers were the standing frame (£504) and 
physiotherapist home visits (£76). Mean costs to the NHS/PSS over the follow-up 
period (adjusted for cost at baseline, EDSS category and region) were approximately 
£539 less for the standing group than the usual care group, excluding the cost of the 
intervention itself. With the addition of the intervention cost, adjusted mean costs to 
the NHS/PSS were approximately £268 greater for the standing group (table 4, and 
appendix, pp 18-26). The amount of informal care used by this population was 
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substantial, and application of a national average hourly rate to this time gave an 
adjusted informal care cost of approximately £3,643 less in the standing group (table 
4, and appendix, pp 18-26). The mean EQ-5D increase from baseline to 36-week 
follow-up was 0.042 for the intervention group and 0.01 for the usual care group. 
This equated to an adjusted mean of 0.018 additional QALYs over the period of 
follow-up (table 4).  
 
The cost-per-QALY of the intervention from the perspective of the NHS/PSS was 
approximately £14,700 (appendix, pp 27). Uncertainty around this estimate is 
illustrated in the cost-effectiveness plane of bootstrapped replicates of incremental 
costs and incremental QALYs (appendix, pp 28). These simulations suggest that on 
87% of occasions the intervention group would have greater QALYs over the period 
of follow-up than the usual care group. The bootstrap replicates also indicate a 0.52 
probability of the intervention being considered cost-effective at a willingness-to-pay 
threshold of £20,000 per QALY and a 0.61 probability at a threshold of £30,000 per 
QALY. Broadening the analysis perspective beyond health and social care, in line 
with the recommendations of the Second Panel on Cost-Effectiveness in Health and 
Medicine26, increased the apparent cost-effectiveness of the intervention. 
 
There were little missing data, and hence multiple imputation was not employed. 
Sensitivity analyses explored: i) the broader societal perspective; ii) taking account of 
the 10-year life of the frames and the NHS’s policy of equipment re-use. For both 
scenarios the intervention appeared dominant in terms of cost-effectiveness 
(appendix, pp 29-30). 
 
Discussion 
Our results provide high-quality evidence that, compared with usual care alone, 
regular frame standing plus usual care provides significant improvement in motor 
function (the primary outcome) in people severely physically impaired with 
progressive severe MS. Statistically significant differences were also found in favour 
of the standing group in terms of hip and ankle joint range and quality of life 
(secondary outcomes). This standing intervention was demonstrated to be feasible 
for people with progressive MS to self-manage with the help of a standing assistant, 
and for physiotherapists to implement within routine clinical practice.  
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Less clear cut is whether the outcome of the standing intervention was clinically 
meaningful. Interpretation is difficult because of the limited evidence to define what 
constitutes an MCID on the AMCA. We relied upon the only two physiotherapy 
studies we were aware of which had used the AMCA; both suggested a nine point 
improvement was clinically relevant in people with severe MS14,24. A nine point 
change could mean, for example, that a person could have improved so that they 
could balance in sitting to dress themselves (3 points), transfer independently (3 
points), and stand without having to use their hands for balance (3 points). However, 
an improvement in any single one of these functional activities may constitute a 
clinically meaningful change. This is supported by the audio narrative accounts of the 
changes experienced by SUMS study participants (see 
https://www.plymouth.ac.uk/research/sums). When considering the design of future 
studies, further exploration is needed regarding the MCID on this measure for 
severely impaired individuals.     
 
Our CACE analysis showed that accounting for compliance to the intervention 
resulted in a larger estimated intervention effect, with the pre-specified MCID of nine 
points on the AMCA scale contained within the CIs for all six compliance definitions. 
This suggests a positive association between compliance with the intervention and 
the motor benefits gained. This is consistent with theoretical expectation, and the 
results of (low methodological quality) studies of standing frame use in other 
neurological populations.6  
 
To sustain any benefits gained from physical activity, individuals need to maintain 
long-term engagement; a particular challenge for people with disability.27 Evidence is 
lacking regarding long-term adherence in people with MS to such interventions, 
however non-adherence rates are as high as 80% for chronic conditions where 
interventions may aim to slow down decline rather thana 'cure'.27  Two-thirds of the 
standing group participants continued to stand regularly in the frame over the 36-
week period, which, in light of the literature, we consider as high. Furthermore, 70% 
requested to keep the frame on completing the study, thus lending support that the 
intervention was both feasible and acceptable.  
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Behavioural change techniques were an integral component of the standing 
intervention. To complement the physiotherapy advice and support, individuals had 
access to paper-based, DVD and online resources, designed to equip them and their 
standing assistants with the knowledge and skills necessary to undertake this activity 
within their own homes. Aimed at enhancing self-efficacy22, this approach was 
considered essential since self-efficacy is a key determinant of physical activity 
behaviour in people with MS28 and is typically low.12  
 
Tolerability of an intervention is important for adherence and so capturing AEs 
potentially associated with the intervention was important. We achieved this using 
daily, self-report, pre-formatted diaries. However, free text description of AEs were 
often ambiguous, making it difficult to determine whether they were new symptoms. 
It is challenging, therefore, to precisely state what proportion of these broad-ranging 
symptoms are related to the standing intervention. Bias in reporting of AEs is also 
possible as the standing group recorded details of each standing session in the 
same diaries, potentially triggering reporting of new symptoms more 
comprehensively than the usual care group. Overall, however, the data suggest this 
intervention is well tolerated; the AEs were typically transient (<7 days), 
musculoskeletal in nature (aches and pains), and occurred early in the programme 
when participants were likely adjusting to recommencement of regular standing. 
Importantly, physiotherapists should inform people that short-term musculoskeletal 
aches and pains may occur, and provide education about how to manage this. From 
a methodological perspective, effective and reliable systems for collecting AE data in 
rehabilitation trials should be further investigated.       
 
There are a number of strengths of this study. To our knowledge this is the largest 
randomised controlled physical rehabilitation study undertaken in severely impaired 
people with progressive MS. It is the first definitive multi-centre RCT to assess the 
clinical and cost-effectiveness, safety and tolerability of a home-based, self-managed 
standing frame programme in this client group. The study was originally planned to 
have 80% power based on conservative assumptions16; with our observed standard 
deviation being lower, and correlation between baseline and week 36 AMCA score 
higher, than anticipated, we are able to estimate the intervention effect with 
increased precision. Our cost-effectiveness analysis assumed that a new standing 
Page 19 of 39 
 
frame would be purchased for everyone in the intervention group; however, given the 
NHS policy of equipment re-use, and the average 10-year life of a frame, our cost-
effectiveness estimate is likely to be conservative.  
 
A further strength is that this is a pragmatic trial. To maximise generalisability of the 
results we minimised our exclusion criteria. The intervention was delivered by 
physiotherapists working within the NHS, who did not undergo specific training to 
deliver the intervention, making it likely that similar results would be gained on 
implementation within usual practice. It is noted, however, that our findings cannot 
automatically be generalised to other countries which do not have a similar 
organisational context. Publication of our educational resources on a freely available 
website (https://www.plymouth.ac.uk/research/sums) aims to enhance shared, 
evidence-based, decision making about the impact of introducing this intervention to 
people’s daily life.  
 
This study has several limitations. Our primary economic outcome measure was 
QALYs, in line with NICE guidance. The difference in EQ-5D scores (used to 
calculate QALYs) between the standing frame and usual care groups at 36-weeks  
does not reach the MCID for the EQ-5D described by Marra et al.29 Therefore, it 
could be argued that the QALY gain is not perceptibly different from zero, implying 
that the intervention is not cost-effective. However, the standing frame intervention 
does appear effective from the patient perspective when considered across outcome 
measures, and specifically according to the primary clinical outcome measure. Our 
main analysis may have been restrictive in identifying benefits of the intervention, 
and a broader societal perspective may have been preferable. 
 
The usual care group was not offered an intervention and hence we cannot exclude 
that placebo effects contributed to the benefits experienced by the standing group. 
However, the primary outcome was clinician-rated and measured by a blinded 
assessor which should limit the impact of this. Nevertheless, further research is 
needed to disentangle the intrinsic effects of standing from non-specific effects due 
to, for example, attention. It is also possible that drug interventions may have 
contributed to any changes. However, participants were excluded if there had been 
any recent changes in disease modifying therapies, and asked to record any 
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medication changes throughout the study period; the two groups were balanced in 
terms of medication changes, hence this is unlikely to account for the between-group 
differences.    
 
In conclusion, there is a paucity of evidence-based, self-management interventions 
which are recommended for people severely impaired with progressive MS who 
have limited available treatment options. We hope this intervention will now be 
offered and reimbursed more widely as a management option for this population.     
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Figure 1: CONSORT Flow Diagram. 
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Figure 2: Fully Adjusted mean difference in the primary outcome, AMCA at 36 
weeks, for (a) the primary analysis and (b) the CACE sensitivity analyses under 
the six compliance definitions, with corresponding 95% confidence interval 
(CIs). 
 
Note: nI is number of participants in intervention group; nTAU is number of participants in 
control group; nC is number of compliers; nNC is number of compliers plus control group 
participants  
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Table 1 – Demographic Data and Baseline Characteristics 
% (n) unless specified Standing 
Group 
(n=71) 
Usual Care 
Group 
(n=69) 
All 
(n=140) 
Mean (sd) [range] Age 
(years) 
58.5 (9.5) 
[34.9, 75.2] 
59.6 (9.3) 
[39.8, 80.7] 
59.1 (9.4) 
[34.9, 80.7] 
     
Mean (sd) [range] EDSS 
Score 
7.3 (0.6) 
[6.5, 8] 
7.2 (0.6) 
[6.5, 8] 
7.3 (0.6) 
[6.5, 8] 
    
EDSS Score    
6.5 33.8 (24) 26.1 (18) 30.0 (42) 
7.0 15.5 (11) 24.6 (17) 20.0 (28) 
7.5 15.5 (11) 23.2 (16) 19.3 (27) 
8.0 35.2 (25) 26.1 (18) 30.7 (43) 
    
Sex    
Male 43.7 (31) 27.5 (19) 35.7 (50) 
Female 56.3 (40) 72.5 (50) 64.3 (90) 
    
Type of MS    
Primary Progressive 39.4 (28) 23.2 (16) 31.4 (44) 
Secondary Progressive 60.6 (43) 76.8 (53) 68.6 (96) 
    
Most Recent Relapse    
> 1 year 87.3 (62) 91.3 (63) 89.3 (125) 
Within three months 2.8 (2) 2.9 (2) 2.9 (4) 
Within six months 2.8 (2) 0.0 (0) 1.4 (2) 
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% (n) unless specified Standing 
Group 
(n=71) 
Usual Care 
Group 
(n=69) 
All 
(n=140) 
Within 12 months 1.4 (1) 2.9 (2.9) 2.1 (3) 
Unknown 5.6 (4) 2.9 (2.9) 4.3 (6) 
    
Occupation    
Unemployed 7.0 (5) 4.3 (3) 5.7 (8) 
Student 0.0 (0) 1.4 (1) 0.7 (1) 
Part Time Work 2.8 (2) 10.1 (7) 6.4 (9) 
Full Time Work 1.4 (1) 1.4 (1) 1.4 (2) 
Age Retired 9.9 (7) 11.6 (8) 10.7 (15) 
Medically Retired 78.9 (56) 71.0 (49) 75.0 (105) 
    
Indoor Walking Aid    
1x Stick 4.2 (3) 2.9 (2) 3.6 (5) 
2x Stick 9.9 (7) 11.6 (8) 10.7 (15) 
Frame 38.0 (27) 43.5 (30) 40.7 (57) 
Wheelchair 66.2 (47) 69.6 (48) 67.9 (95) 
    
Outdoor Walking Aid    
1x Stick 2.8 (2) 2.9 (2) 2.9 (4) 
2x Stick 8.5 (6) 8.7 (6) 8.6 (12) 
Frame  15.5 (11) 21.7 (15) 18.6 (26) 
Wheelchair 94.4 (67) 92.8 (64) 93.6 (131) 
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% (n) unless specified Standing 
Group 
(n=71) 
Usual Care 
Group 
(n=69) 
All 
(n=140) 
    
Wheelchair Use    
None 5.6 (4) 5.8 (4) 5.7 (8) 
Occasionally 5.6 (4) 4.3 (3) 5.0 (7) 
Monthly 2.8 (2) 1.4 (1) 2.1 (3) 
Weekly 18.3 (13) 14.5 (10) 16.4 (23) 
Daily 67.6 (48) 73.9 (51) 70.7 (99) 
    
Medical History    
Nil of note 19.7 (14) 18.8 (13) 19.3 (27) 
Osteoarthritis 8.5 (6) 13.0 (9) 10.7 (15) 
CHD/Hypertension 21.1 (15) 13.0 (9) 17.1 (24) 
Diabetes 11.3 (8) 1.4 (1) 6.4 (9) 
COPD 8.5 (6) 1.4 (1) 5.0 (7) 
Migraine 9.9 (7) 7.2 (5) 8.6 (12) 
Other Neurological 5.6 (4) 4.3 (3) 5.0 (7) 
Depression 38.0 (27) 43.5 (30) 40.7 (57) 
Osteoporosis 7.0 (5) 11.6 (8) 9.3 (13) 
Other 35.2 (25) 33.3 (23) 34.3 (48) 
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Table 2 – Primary Outcome: AMCA score at 36 weeks. Primary Intention to Treat (ITT) Analysis and Complier Average 
Causal Effect (CACE) Sensitivity Analyses 
 
 Mean (sd) [range] of AMCA Fully Adjusted Analysis1 Analysis Adjusted for 
Baseline only 
 Standing Frame  
(n=71) 
Usual Care  
(n=69) 
Mean Difference  
(Standing – Usual Care) 
(95% CI) 
Mean Difference  
(Standing – Usual Care) 
(95% CI)  Baseline Week 36 Baseline Week 36 
 (n=71)2 (n=61)2 (n=69)2 (n=61)2 
ITT Analysis 
26.1 (13.9) 
[3.0, 59.0] 
29.3 (17.2) 
[1.0, 68.0] 
30.2 (14.6) 
[6.0, 66.0] 
28.2 (17.0) 
[0.0, 68] 
4.7  
(1.9, 7.5) 
p=0.001 
4.6 
(1.6, 7.6) 
p=0.003 
     
 Compliers Non-compliers + Usual Care   
CACE:   
Best 16 
Weeks 
(n = 49)2 (n=46)2 (n=91)2 (n=76)2   
26.2 (13.7) 
[3, 56] 
29.9 (16.0) 
[6, 65] 
29.1 (14.6) 
[6, 66] 
28.4 (17.5) 
[1, 68] 
6.1 
(2.5, 9.8) 
p=0.001 
6.1 
(2.2, 9.9) 
p=0.002 
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CACE: 
Worst 16 
Weeks 
(n=36)2 (n=35)2 (n=104)2 (n=87)2   
28.2 (13.4) 
[8, 56] 
31.6 (16.4) 
[8, 65] 
28.1 (14.7) 
[3, 66] 
27.9 (17.1) 
[1, 68] 
7.9 
(3.1, 12.8) 
p=0.001 
7.9 
(2.8, 13.0) 
p=0.003 
CACE: 
Weeks  
5-20 
(n=46)2 (n=43)2 (n=94)2 (n=79)2   
26.7 (14.0) 
[3, 56] 
30.5 (15.9) 
[6, 65] 
28.8 (14.5) 
[6, 66] 
28.1 (17.5) 
[1, 68]                                   
6.5 
(2.6, 10.4) 
p=0.001 
6.5 
(2.3, 10.6) 
p=0.002 
CACE:   
Best 32 
Weeks 
(n =46)2 (n=43)2 (n=94)2 (n=79)2   
26.6 (14.0) 
[3, 56] 
32.4 (16.6) 
[6, 65] 
28.0 (14.5) 
[6, 66] 
27.7 (17.5) 
[1, 68] 
6.5 
(2.7, 10,4) 
p=0.001 
6.5  
(2.4, 10.5) 
p=0.002 
CACE: 
Worst 32 
Weeks 
(n=36)2 (n=35)2 (n=104)2 (n=87)2   
28.4 (13.9) 
[8, 56] 
32.4 (16.6) 
[6, 65] 
28.0 (14.5) 
[3, 66] 
27.5 (16.9) 
[1, 68] 
7.9 
(3.1, 12.7) 
p=0.001 
7.8 
(2.8, 12.9) 
p=0.002 
CACE: 
Weeks 
(n=42)2 (n=41)2 (n=98)2 (n=81)2   
27.3 (13.8) 31.9 (15.7) 28.5 (14.6) 27.5 (17.4) 6.8 6.8 
Page 34 of 39 
 
5-36 [3, 56] [6, 65] [4, 66] [1, 68] (2.8, 10.8) 
p=0.001 
(2.6, 11.0) 
p=0.002 
1 Adjusted for baseline AMCA Score, region and EDSS category; 2 n is the total number of participants who provided data at that time point 
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Table 3  
Self-reported adverse events according to allocated group  
Self-reported Symptoms lasting < 7 
days  
Usual Care group  
(n = number of events*)  
Standing Frame group  
(n = number of events*)  
  
Pain  
 
Categorised according to organ 
classification 
Musculoskeletal 
Neurological  
Abdominal  
Gynaecological 
Renal  
Respiratory 
 
180 
 
 
 
160  
12  
6 
2 
0 
0 
551  
 
 
 
486  
16  
9 
0 
2 
1 
Spasms 197 231 
Fatigue  184 60 
Urinary tract infection  36 45 
Numbness / sensory disturbance  33 41 
Tremor /shaking 24 7 
Weakness 23 24 
Constipation / diarrhoea 17 7 
Vertigo 9 22 
Virus 5 31 
Chest Infection  5 16 
Leg or back stiffness/ tightness  2 23 
Headache 3 3 
Visual disturbance 3 3 
Seizures 2 0 
Balance problems 2 5 
Loss of bladder control 2 0 
Slurred speech 1 0 
Multiple Sclerosis Relapse 1 1 
Confusion 1 0 
Rash 1 0 
Toe infection 1 0 
Shingles 1 0 
Bladder spasms 1 2 
Blood in urine 1 0 
Nausea /vomiting 1 2 
Low sodium 0 1 
Ankle swelling 0 4 
Depression 0 1 
Shortness of breath 0 3 
Tennis elbow 0 1 
Low blood pressure 0 3 
Bruising 0 1 
Total number of adverse events* 
lasting < 7 days  
736 1188 
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Adverse events lasting >7days  Usual Care group 
(n=number of 
participants) 
Standing Frame group 
(n=number of 
participants) 
Urinary tract infection  4  10  
Chest infection 5  10  
Nervous system:  
Spasms 
Fatigue 
Weakness 
Stiff legs   
6  
4  
1 
1 
0 
4  
2 
2 
0 
1 
Bowel difficulties  3 0  
Infection  0  1 
Psychiatric (depression) 0  1 
Musculoskeletal pain  3   
coccyx pain (18 days)  
heel pain (9 days) 
hip pain (22 days)  
2  
back pain (11 days)  
joint ache (14 days) 
Total number of participants 
reporting adverse events lasting > 7 
days  
21 28 
 
*n = the number of days on which the adverse event was self-reported (i.e. event days rather 
than number of participants reporting the adverse event)   
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Table 4 – Estimated costs and EQ-5D values by group, and adjusted cost and adjusted QALYs differences, over 36-week 
follow-up 
 
 Standing frame intervention 
(n=71) 
Usual care (n=69) Difference adjusted for 
baseline covariates* 
    
Resource item n Mean (SD) £ n Mean (SD) £ Mean (95% CI)** £ 
Primary care 65 594.58 (831.29)          62 470.46 (681.94) 15.79  
(-199.74, 248.23) 
Secondary care 65 1,787.40 (4,155.02) 62 2,074.17 (3,836.70) -284.82 
(-1,368.04, 1,077.62) 
Personal social services 65 477.58 (1,359.09)          
 
62 947.28 (3,086.93) -10.78 
(-408.81, 369.46) 
Total NHS/PSS (excluding 
standing frame intervention) 
65 2,859.56 (4,958.43) 62 3,491.91 (5,408.15) -539.27 
(-1,953.60, 1,138.40) 
Standing frame intervention 54 807.74 - - - 
Total NHS/PSS 65 3,667.30 (4,958.43) 62 3,491.91 (5,408.15) 268.47 
(-1,093.79,  2,051.38) 
Patient personal costs 65 2,999.25 (6,951.45) 62 2,117.50 (3,437.69)        709.07 
(-998.70, 2,469.58) 
Informal care 65 16,047.16 (9,944.57) 
 
62 18,624.35 (13,589.22)           
 
-3,643.34 
(-6,020.19, -1,348.18) 
Total costs (NHS, PSS, patient 
and informal care) 
65 21,905.97 (12,147.65)    
 
62 24,233.75 (13,464.93)     
 
-2,192.41 
(-5,755.23, 1,163.43) 
      
Measure: time point n Mean (SD) 
[range] 
n Mean (SD) 
[range] 
Mean (95% CI)** 
EQ-5D: Baseline 71 
 
0.224 (0.272) 
[-0.352 to 0.813] 
69 0.251 (0.274) 
[-0.265 to 0.778] 
 
EQ-5D: 20 weeks 68 0.294 (0.269) 
[-0.256 to 0.813] 
63 0.271 (0.304) 
[-0.319 to 0.779] 
 
EQ-5D: 36 weeks 65 0.266 (0.303) 
[-0.307 to 0.767] 
63 
 
0.262 (0.293) 
[-0.358 to 0.836] 
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QALYs (based on the EQ-5D) 
over the 36-week follow-up 
65 0.189 (0.174) 
[-0.125 to 0.549] 
62 0.183 (0.182) 
[-0.142 to 0.544] 
0.018 
(-0.014, 0.051) 
*Cost (specific to each cost component)/EQ-5D value at baseline, EDSS category (>=7.5,<7.5) at baseline, and region   
** From bootstrap with 10,000 replication.   
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